Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin

E Maubec, P Petrow, I Scheer-Senyarich… - Journal of Clinical …, 2011 - ascopubs.org
Purpose To evaluate the efficacy and safety of cetuximab, a monoclonal antibody that
inhibits the epidermal growth factor receptor (EGFR), as a first-line monotherapy in patients …
被引用次数：477 相关文章

Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin

E Maubec, P Petrow, I Scheer-Senyarich… - Journal of Clinical …, 2011 - cir.nii.ac.jp
< jats: sec>< jats: title> Purpose</jats: title>< jats: p> To evaluate the efficacy and safety of
cetuximab, a monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR) …

Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.

E Maubec, P Petrow, I Scheer-Senyarich… - Journal of Clinical …, 2011 - europepmc.org
Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable
squamous cell carcinoma of the skin. - Abstract - Europe PMC Sign in | Create an account …

[引用][C] Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin

E MAUBEC, P PETROW… - Journal of clinical …, 2011 - pascal-francis.inist.fr
Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With
Unresectable Squamous Cell Carcinoma of the Skin CNRS Inist Pascal-Francis CNRS …
[PDF] archive.org

[PDF][PDF] Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin

E Maubec, P Petrow, I Scheer-Senyarich… - J Clin …, 2011 - scholar.archive.org
Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable
Squamous Cell Carcinoma of the Skin Page 1 Phase II Study of Cetuximab As First-Line …
[PDF] researchgate.net

[PDF][PDF] Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin

E Maubec, P Petrow, I Scheer-Senyarich, P Duvillard… - 2011 - researchgate.net
Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable
Squamous Cell Carcinoma of the Skin Page 1 Phase II Study of Cetuximab As First-Line …
[PDF] bichat-larib.com

[PDF][PDF] Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin

E Maubec, P Petrow, I Scheer-Senyarich, P Duvillard… - J Clin …, 2011 - bichat-larib.com
Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable
Squamous Cell Carcinoma of the Skin Page 1 Phase II Study of Cetuximab As First-Line …

Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin

E Maubec, P Petrow… - Journal of clinical …, 2011 - pubmed.ncbi.nlm.nih.gov
Purpose To evaluate the efficacy and safety of cetuximab, a monoclonal antibody that
inhibits the epidermal growth factor receptor (EGFR), as a first-line monotherapy in patients …

[引用][C] Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin

E MAUBEC, P PETROW… - Journal of …, 2011 - American Society of Clinical …